Home › Research › Clinical trials
Clinical trials
Every Alzheimer's trial in our copy of the ClinicalTrials.gov registry — completed, running and abandoned. Filter it, then follow the link to the official record.
If you are thinking about joining a trial
A listing here is a record that a study was registered. It is not a recommendation, and it does not mean the study is still recruiting or that anyone is eligible. Registry entries go stale.
Talk to the treating doctor first, then contact the study team listed on the official ClinicalTrials.gov record. The NIA's free referral line can help you look: 1-800-438-4380, weekdays, English and Spanish.
Showing 5,426–5,450 of 7,816 matching trials · page 218 of 313, 25 per page.
Sorted by the date the registry record was last updated, newest first. This page never loads all 7,816 rows at once — use the CSV download if you want the whole file.
| Trial | Phase | Status | Enrolled | Sponsor | Last updated |
|---|---|---|---|---|---|
|
CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects NCT03713892 CKD-504; Placebo Runs in: South Korea · 1 site |
PHASE1 other |
UNKNOWN | 88 | Chong Kun Dang Pharmaceutical INDUSTRY |
2020-02-24 |
|
Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD NCT03819699 Lu AF20513; booster vaccine Runs in: Finland; Sweden · 3 sites |
PHASE1 other |
TERMINATED | 3 | H. Lundbeck A/S INDUSTRY |
2020-02-21 |
|
Non-pharmacological Intervention for Preclinical Alzheimer's Disease NCT04279418 Mixed functional foods supplementation; Placebo Runs in: China · 1 site |
NA other |
COMPLETED | 60 | XuanwuH 2 OTHER |
2020-02-21 |
|
Multicomponent Intervention in Caregivers on Quality of Life of People With Dementia: a Clinical Trial NCT04280861 Multicomponent Intervention Runs in: Spain · 1 site |
NA other |
UNKNOWN | 94 | Consorci Hospitalari de Vic OTHER |
2020-02-21 |
|
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab NCT01723826 Crenezumab Runs in: Canada; France; Germany; Spain; United Kingdom; United States · 86 sites |
PHASE2 anti-amyloid-antibody |
COMPLETED | 360 | Genentech, Inc. INDUSTRY |
2020-02-20 |
|
Protocol of Multi-domain Attention Training NCT03379519 Multi-domain Attention Training (MAT); Passive information activities (PIA) |
NA other |
COMPLETED | 60 | Ministry of Science and Technology, Taiwan OTHER_GOV |
2020-02-20 |
|
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density NCT03577262 [11C]-UCB-J Runs in: Netherlands · 3 sites |
EARLY_PHASE1 other |
COMPLETED | 19 | Alkermes, Inc. INDUSTRY |
2020-02-20 |
|
Comparative Trial of Home-Based Palliative Care NCT03694431 Tech-supported HBPC; Standard HBPC Runs in: United States · 2 sites |
NA other |
TERMINATED | 3,999 | Kaiser Permanente OTHER |
2020-02-20 |
|
Nilotinib in Huntington's Disease NCT03764215 Nilotinib 150 MG Runs in: United States · 1 site |
PHASE1 other |
UNKNOWN | 10 | Georgetown University OTHER |
2020-02-20 |
|
Identifying the Course of Dementia Using Medical Records: the CoMed Study NCT03817138 Exposures: Markers of disease progression Runs in: United Kingdom · 1 site |
NA other |
COMPLETED | 258 | Keele University OTHER |
2020-02-20 |
|
The Safety and Scientific Validity of Low-dose Whole Brain Radiotherapy in Alzheimer's Disease. NCT04203121 low dose whole brain radiation to treat Alzheimer disease Runs in: South Korea · 1 site |
NA other |
UNKNOWN | 10 | Kyung Hee University Hospital at Gangdong OTHER |
2020-02-20 |
|
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment NCT02240459 fesoterodine 4mg; Oxybutynin; placebo; fesoterodine 8mg Runs in: Canada · 1 site |
PHASE2 other |
COMPLETED | 47 | University of Alberta OTHER |
2020-02-19 |
|
Caregiver Study Dr. Phillips NCT03653871 Performing Arts Instruction Runs in: United States · 1 site |
NA other |
COMPLETED | 75 | AdventHealth OTHER |
2020-02-19 |
|
Decoding Presymptomatic White Matter Changes in Huntington Disease NCT03193099 Brain imaging; Neurological assessments; Psychological assessments;... Runs in: France · 1 site |
NA other |
COMPLETED | 60 | Institut National de la Santé Et de la Recherche Médicale, France OTHER_GOV |
2020-02-18 |
|
Multicentre Study About the Effect of Individual Reminiscence Therapy NCT04047238 Reminiscence Therapy Runs in: Portugal · 25 sites |
NA other |
COMPLETED | 251 | Rsocialform - Geriatria, Lda OTHER |
2020-02-18 |
|
Assessing Dementia Risk in the Community: The Dementia Population Risk Tool NCT03155815 |
NA other |
COMPLETED | 75,460 | Ottawa Hospital Research Institute OTHER |
2020-02-17 |
|
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET NCT03545789 [18F]MNI-958 Runs in: United States · 1 site |
PHASE1 other |
COMPLETED | 16 | Invicro OTHER |
2020-02-17 |
|
Efficacy of Computerized Cognitive Training in the Elderly With Mild Cognitive Impairment NCT03577717 computerized cognitive training; occupational therapy Runs in: Taiwan · 1 site |
NA other |
TERMINATED | 7 | Taipei Hospital, Taiwan OTHER |
2020-02-17 |
|
What Are my Options to Stay Safe at Home: Technology For Aging at Home NCT04267484 GPS and travel diary; e-decision support platform Runs in: Canada; Netherlands; Sweden · 4 sites |
NA other |
UNKNOWN | 294 | CHU de Quebec-Universite Laval OTHER |
2020-02-17 |
|
Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease NCT04271163 MemorEM Runs in: United States · 1 site |
PHASE1|PHASE2 other |
UNKNOWN | 6 | NeuroEM Therapeutics, Inc. INDUSTRY |
2020-02-17 |
|
Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment NCT00361062 comparative computer simulation Runs in: Israel · 2 sites |
NA other |
COMPLETED | 60 | HaEmek Medical Center, Israel OTHER |
2020-02-13 |
|
Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients NCT04094129 Wismemo; Placebo |
NA other |
WITHDRAWN | 0 | GenMont Biotech Incorporation INDUSTRY |
2020-02-13 |
|
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil NCT02711683 DL-3-n-butylphthalide; Donepezil Runs in: China · 1 site |
NA symptomatic-cholinergic |
COMPLETED | 92 | First Affiliated Hospital Xi'an Jiaotong University OTHER |
2020-02-12 |
|
Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients. NCT00733863 Placebo; CAD106 Runs in: France; Sweden; Switzerland; United Kingdom · 4 sites |
PHASE2 other |
COMPLETED | 27 | Novartis INDUSTRY |
2020-02-11 |
|
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients NCT00956410 CAD106 Runs in: France; Sweden; Switzerland; United Kingdom · 4 sites |
PHASE2 other |
COMPLETED | 21 | Novartis INDUSTRY |
2020-02-11 |
This table is wider than a phone screen — swipe it sideways to see the rest.
Where these trials come from
- Registry
- ClinicalTrials.gov, pulled through their public API (v2)
- Trials in the file
- 7,816
- Source file
- trials.csv (3.8 MB, 7816 rows)
- Basis
- Measured These are registry records as submitted by each study's sponsor.
What could make this misleading
Sponsors enter their own data and do not always keep it current, so "recruiting" can be out of date by months or years. Enrollment figures may be targets rather than actual numbers; the downloaded file says which for each trial. Trials that were never registered do not appear at all, and the intervention class is this project's own grouping, not the registry's.
Always check the official record before acting on anything here. This is a summary, not medical advice.
From the research library
The highest-scoring studies we hold on this subject, each summarised in plain English. Scores are alzhub's usefulness score, not a verdict on the science.
Clinical trials
- MINocyclinE to Reduce inflammation and blood-brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double-blind, placebo-controlled experimental medicine trial
- Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
- Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial
- Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease
- Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial